# Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

> **NCT01870284** · PHASE3 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Spondylitis, Ankylosing

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Placebo
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT01870284
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2016-04
- **Final completion:** 2018-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to unexpected operational issues outside of Lilly's control the study has been closed
- **Last updated:** 2014-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870284, "Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01870284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*